3D Medicines (HKG:1244) narrowed its attributable loss to 89.4 million yuan in the first half of 2025 from 103.5 million yuan a year prior, an Aug. 29 Hong Kong bourse filing said.

Shares of the biopharmaceutical company were down nearly 3% in Monday afternoon trading.

Loss per share was 0.36 yuan, down from 0.42 yuan in the year-ago period.

Revenue for the interim period jumped 1.3% to 209.2 million yuan from 206.4 million yuan in the corresponding period of the last year, mainly due to a stable sales revenue.